AMS
American Shared Hospital Services
AMS lost money over the past year, so it has no meaningful PE right now.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AMS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Weak |
AMS's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AMS PE Valuation
AMS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AMS Forward outlook
There aren't enough analyst estimates for AMS to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AMS Earnings Per Share
AMS and HIMS do not have enough comparable growth data to identify a winner.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.4M | +19% |
| Q1 2026 | $7.1M | +16% |
| Q4 2025 | $7.7M | -15% |
| Q3 2025 | $7.2M | +2.5% |
| Q2 2025 | $7.1M | +0.2% |
| Q1 2025 | $6.1M | +17% |
| Q4 2024 | $9.1M | +59% |
| Q3 2024 | $7M | +36% |
AMS's revenue has held roughly level: $8M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11% | -3.1 points |
| Q1 2026 | -13% | +8.2 points |
| Q4 2025 | -18% | +2.1 points |
| Q3 2025 | -4.8% | +7.9 points |
| Q2 2025 | -7.7% | -7.7 points |
| Q1 2025 | -21% | -20 points |
| Q4 2024 | -20% | -27 points |
| Q3 2024 | -13% | -14 points |
AMS's operating margin was โ11% last quarter, down 3.1 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AMS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over AMS on profitability, with a higher operating margin.
AMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.2M | +$4.5M |
| Q1 2026 | $2.1M | +$3.6M |
| Q4 2025 | $1.3M | +$5.7M |
| Q3 2025 | -$2M | -$1.6M |
| Q2 2025 | -$2.3M | -3347% |
| Q1 2025 | -$1.5M | +$1.5M |
| Q4 2024 | -$4.4M | -$1.2M |
| Q3 2024 | -$407K | -$356K |
AMS's free cash flow has turned positive after two years mostly in the red: $4M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AMS on cash flow, with more consistent year-over-year improvement.
AMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 5.3x | High |
| Q1 2026 | 5.1x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 4.7x | High |
| Q1 2025 | 3.8x | Elevated |
| Q4 2024 | 2.7x | Moderate |
| Q3 2024 | 0.1x | Very low |
AMS's net debt is about 5.3 years of its operating earnings (EBITDA), up from 4.7 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over AMS on leverage, with a lower net debt burden relative to earnings.
AMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.1 | Neutral |
| Stochastic | 11.8 | Oversold |
AMS's weekly RSI is 30 (neutral) and its Stochastic is 12 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AMS PE vs Healthcare Sector
| Metric | AMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
AMS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
HIMS has no meaningful PE right now: it lost money over the past year.
AMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.28 | 15% below |
| 20 week MA | $1.39 | 22% below |
| 50 week MA | $1.66 | 34% below |
| 100 week MA | $2.15 | 49% below |
| 200 week MA | $2.51 | 57% below |
AMS is in a downtrend: it's below all five of its weekly moving averages, and 57% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.56 | $2.10 | -18% |
| 2021 | $2.10 | $2.42 | +15% |
| 2022 | $2.42 | $2.81 | +16% |
| 2023 | $2.81 | $2.38 | -15% |
| 2024 | $2.38 | $3.19 | +34% |
| 2025 | $3.19 | $2.14 | -33% |
| 2026 YTD | $2.14 | $1.09 | -49% |
AMS has finished lower in three of the last six years. It's down 49% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over AMS on returns for 2026, with the stronger performance.